Shares of Neos Therapeutics Inc. (NASDAQ:NEOS) fell 4.6% during trading on Friday . The stock traded as low as $8.75 and last traded at $8.75, with a volume of 67,657 shares traded. The stock had previously closed at $9.17.

Several brokerages have recently commented on NEOS. Royal Bank Of Canada decreased their target price on Neos Therapeutics from $33.00 to $29.00 and set an “outperform” rating for the company in a research report on Tuesday, May 17th. Zacks Investment Research cut Neos Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 18th. BMO Capital Markets reiterated a “buy” rating and set a $15.00 price objective on shares of Neos Therapeutics in a report on Tuesday, July 19th. Finally, Wells Fargo & Co. reiterated a “buy” rating on shares of Neos Therapeutics in a report on Wednesday, May 18th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $21.75.

The stock’s market capitalization is $142.00 million. The stock has a 50 day moving average of $9.48 and a 200 day moving average of $9.90.

Neos Therapeutics (NASDAQ:NEOS) last issued its earnings results on Monday, May 16th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.87) by $0.08. Equities research analysts predict that Neos Therapeutics Inc. will post ($4.88) EPS for the current year.

In related news, insider Juergen Martens purchased 10,000 shares of the stock in a transaction on Monday, June 13th. The shares were purchased at an average cost of $9.90 per share, with a total value of $99,000.00. Following the acquisition, the insider now directly owns 10,000 shares in the company, valued at $99,000. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Gregory J. Robitaille purchased 7,442 shares of the stock in a transaction on Wednesday, May 18th. The stock was bought at an average cost of $7.55 per share, for a total transaction of $56,187.10. Following the completion of the acquisition, the director now owns 55,677 shares in the company, valued at $420,361.35. The disclosure for this purchase can be found here.

A hedge fund recently raised its stake in Neos Therapeutics stock. Marshall Wace LLP increased its stake in shares of Neos Therapeutics Inc. (NASDAQ:NEOS) by 11.5% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 96,162 shares of the company’s stock after buying an additional 9,929 shares during the period. Marshall Wace LLP owned approximately 0.60% of Neos Therapeutics worth $1,377,000 as of its most recent filing with the SEC.

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.